Epicrispr builds case for FSHD treatment with updated data for EPI-321
Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve people have been dosed with the therapy, EPI-321, as part of the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.